1. Home
  2. DMAC

DMAC

DiaMedica Therapeutics Inc.

Logo DiaMedica Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.

Founded: 2000 Country:
United States
United States
Employees: N/A City: MINNEAPOLIS
Market Cap: 94.5M IPO Year: N/A
Target Price: $7.00 AVG Volume (30 days): 41.3K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.60 EPS Growth: N/A
52 Week Low/High: $1.50 - $4.75 Next Earning Date: 05-13-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: